Association between lipid profiles and viral respiratory infections in human sputum samples.
Bayesian regression
Influenza
Lipidomics
Sputum
Viral infection
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
02 Jul 2022
02 Jul 2022
Historique:
received:
24
02
2022
accepted:
13
06
2022
entrez:
2
7
2022
pubmed:
3
7
2022
medline:
7
7
2022
Statut:
epublish
Résumé
Respiratory infections such as influenza account for significant global mortality each year. Generating lipid profiles is a novel and emerging research approach that may provide new insights regarding the development and progression of priority respiratory infections. We hypothesized that select clusters of lipids in human sputum would be associated with specific viral infections (Influenza (H1N1, H3N2) or Rhinovirus). Lipid identification and semi-quantitation was determined with liquid chromatography and high-resolution mass spectrometry in induced sputum from individuals with confirmed respiratory infections (influenza (H1N1, H3N2) or rhinovirus). Clusters of lipid species and associations between lipid profiles and the type of respiratory viral agent was determined using Bayesian profile regression and multinomial logistic regression. More than 600 lipid compounds were identified across the sputum samples with the most abundant lipid classes identified as triglycerides (TG), phosphatidylethanolamines (PE), phosphatidylcholines (PC), Sphingomyelins (SM), ether-PC, and ether-PE. A total of 12 lipid species were significantly different when stratified by infection type and included acylcarnitine (AcCar) (10:1, 16:1, 18:2), diacylglycerols (DG) (16:0_18:0, 18:0_18:0), Lysophosphatidylcholine (LPC) (12:0, 20:5), PE (18:0_18:0), and TG (14:1_16:0_18:2, 15:0_17:0_19:0, 16:0_17:0_18:0, 19:0_19:0_19:0). Cluster analysis yielded three clusters of lipid profiles that were driven by just 10 lipid species (TGs and DGs). Cluster 1 had the highest levels of each lipid species and the highest prevalence of influenza A H3 infection (56%, n = 5) whereas cluster 3 had lower levels of each lipid species and the highest prevalence of rhinovirus (60%; n = 6). Using cluster 3 as the reference group, the crude odds of influenza A H3 infection compared to rhinovirus in cluster 1 was significantly (p = 0.047) higher (OR = 15.00 [95% CI: 1.03, 218.29]). After adjustment for confounders (smoking status and pulmonary comorbidities), the odds ratio (OR) became only marginally significant (p = 0.099), but the magnitude of the effect estimate was similar (OR = 16.00 [0.59, 433.03]). In this study, human sputum lipid profiles were shown to be associated with distinct types of viral infection. Better understanding the relationship between respiratory infections of global importance and lipids contributes to advancing knowledge of pathogenesis of infections including identifying populations with increased susceptibility and developing effective therapeutics and biomarkers of health status.
Sections du résumé
BACKGROUND
BACKGROUND
Respiratory infections such as influenza account for significant global mortality each year. Generating lipid profiles is a novel and emerging research approach that may provide new insights regarding the development and progression of priority respiratory infections. We hypothesized that select clusters of lipids in human sputum would be associated with specific viral infections (Influenza (H1N1, H3N2) or Rhinovirus).
METHODS
METHODS
Lipid identification and semi-quantitation was determined with liquid chromatography and high-resolution mass spectrometry in induced sputum from individuals with confirmed respiratory infections (influenza (H1N1, H3N2) or rhinovirus). Clusters of lipid species and associations between lipid profiles and the type of respiratory viral agent was determined using Bayesian profile regression and multinomial logistic regression.
RESULTS
RESULTS
More than 600 lipid compounds were identified across the sputum samples with the most abundant lipid classes identified as triglycerides (TG), phosphatidylethanolamines (PE), phosphatidylcholines (PC), Sphingomyelins (SM), ether-PC, and ether-PE. A total of 12 lipid species were significantly different when stratified by infection type and included acylcarnitine (AcCar) (10:1, 16:1, 18:2), diacylglycerols (DG) (16:0_18:0, 18:0_18:0), Lysophosphatidylcholine (LPC) (12:0, 20:5), PE (18:0_18:0), and TG (14:1_16:0_18:2, 15:0_17:0_19:0, 16:0_17:0_18:0, 19:0_19:0_19:0). Cluster analysis yielded three clusters of lipid profiles that were driven by just 10 lipid species (TGs and DGs). Cluster 1 had the highest levels of each lipid species and the highest prevalence of influenza A H3 infection (56%, n = 5) whereas cluster 3 had lower levels of each lipid species and the highest prevalence of rhinovirus (60%; n = 6). Using cluster 3 as the reference group, the crude odds of influenza A H3 infection compared to rhinovirus in cluster 1 was significantly (p = 0.047) higher (OR = 15.00 [95% CI: 1.03, 218.29]). After adjustment for confounders (smoking status and pulmonary comorbidities), the odds ratio (OR) became only marginally significant (p = 0.099), but the magnitude of the effect estimate was similar (OR = 16.00 [0.59, 433.03]).
CONCLUSIONS
CONCLUSIONS
In this study, human sputum lipid profiles were shown to be associated with distinct types of viral infection. Better understanding the relationship between respiratory infections of global importance and lipids contributes to advancing knowledge of pathogenesis of infections including identifying populations with increased susceptibility and developing effective therapeutics and biomarkers of health status.
Identifiants
pubmed: 35780155
doi: 10.1186/s12931-022-02091-w
pii: 10.1186/s12931-022-02091-w
pmc: PMC9250719
doi:
Substances chimiques
Lysophosphatidylcholines
0
Phosphatidylcholines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
177Informations de copyright
© 2022. The Author(s).
Références
Crit Care. 2019 Jul 19;23(1):258
pubmed: 31324202
Diagn Microbiol Infect Dis. 2016 Jun;85(2):249-54
pubmed: 27105773
Front Immunol. 2019 Apr 16;10:785
pubmed: 31040846
Eur Respir J. 2013 Sep;42(3):802-25
pubmed: 23397306
J Biol Chem. 1995 Dec 8;270(49):29279-85
pubmed: 7493959
Anal Chem. 2015;87(9):4957-64
pubmed: 25884268
Ann Lab Med. 2012 Mar;32(2):133-8
pubmed: 22389880
Biomark Med. 2015;9(2):153-68
pubmed: 25689902
J Biol Chem. 1957 May;226(1):497-509
pubmed: 13428781
J Proteome Res. 2014 Sep 5;13(9):3919-29
pubmed: 25040188
Cell Host Microbe. 2016 Feb 10;19(2):254-66
pubmed: 26867183
J Lipid Res. 2018 Sep;59(9):1671-1684
pubmed: 29946055
FEMS Microbiol Rev. 2021 Aug 17;45(4):
pubmed: 33512504
J Allergy Clin Immunol. 2016 Mar;137(3):734-43.e1
pubmed: 26255695
J Clin Microbiol. 1999 Dec;37(12):3971-4
pubmed: 10565916
Curr Opin Cell Biol. 2016 Apr;39:28-36
pubmed: 26895312
BMC Bioinformatics. 2017 Jul 10;18(1):331
pubmed: 28693421
Am J Med. 2002 Apr 22;112 Suppl 6A:28S-32S
pubmed: 11955457
Int J Environ Res Public Health. 2017 May 09;14(5):
pubmed: 28486423
J Asthma. 2012 Aug;49(6):593-9
pubmed: 22765313
MMWR Morb Mortal Wkly Rep. 2018 Jan 19;67(2):53-59
pubmed: 29346338
Pan Afr Med J. 2018 Mar 26;29:174
pubmed: 30050638
Cell. 2015 Jul 2;162(1):170-83
pubmed: 26095250
BMJ. 1996 Nov 2;313(7065):1119-23
pubmed: 8916700
BMC Pulm Med. 2014 Feb 01;14:10
pubmed: 24484629
J Lipid Res. 2014 Jul;55(7):1357-65
pubmed: 24868094
Clin Ther. 2001 Oct;23(10):1615-27
pubmed: 11726001
Am J Physiol Lung Cell Mol Physiol. 2016 Dec 1;311(6):L1160-L1169
pubmed: 27836900
Semin Immunol. 2013 Oct 31;25(3):240-8
pubmed: 24084369
Metabolomics. 2018 Sep 17;14(10):123
pubmed: 30830396
Tohoku J Exp Med. 2016;240(2):131-139
pubmed: 27725531
Cell. 2013 Mar 28;153(1):112-25
pubmed: 23477864
J Med Virol. 2014 Dec;86(12):2122-7
pubmed: 24797344
Am J Med. 2015 Nov;128(11):1251.e11-20
pubmed: 26087047
Am J Respir Crit Care Med. 2014 Jul 15;190(2):155-64
pubmed: 24871890
J Occup Environ Med. 2014 Oct;56(10):1088-93
pubmed: 25285832
Curr Environ Health Rep. 2018 Mar;5(1):59-69
pubmed: 29427169
Allergy. 2014 Apr;69(4):527-36
pubmed: 24571371